台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

國光生

(4142)
可現股當沖
  • 股價
    27.50
  • 漲跌
    ▲0.20
  • 漲幅
    +0.73%
  • 成交量
    700
  • 產業
    上市 生技醫療類股
  • 635人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
國光生 (4142)籌碼相關-港商麥格理 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

港商麥格理 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/05/1700.00327.8228.25-3947-0.32%
2024/05/1500.006227.7227.70-621,024-6.05%
2024/04/2931727.5200.0027.553171,09928.84% 大買/鉅額交易
2024/04/1600.00225.3025.30-2935-0.21%
2024/04/0800.00526.2926.30-5942-0.53%
2024/01/3100.002530.5530.55-251,030-2.43%
2024/01/3000.006130.9130.80-611,042-5.85%
2023/11/301435.7100.0035.70149021.55%
2023/10/31931.8000.0031.8097601.18%
2023/09/155033.6500.0033.65508485.89%
2023/05/311338.7500.0038.75132,1630.60%
2023/03/1700.002138.6538.65-212,975-0.71%
2023/02/1600.00839.9039.90-82,078-0.38%
2023/02/0100.00739.6539.65-71,701-0.41%
2022/12/21136.0500.0035.5011,6520.06%
2022/12/1600.001735.6035.60-171,560-1.09%
2022/12/07336.6800.0036.5031,6180.19%
2022/09/162136.5500.0036.55213,7100.57%
2022/09/081838.5500.0038.55183,8510.47%
2022/08/231338.4000.0038.40133,4130.38%
2022/07/20238.6800.0039.1023,2210.06%
2022/07/1915538.3300.0038.001553,2344.79% 大買/鉅額交易
2022/07/141639.1500.0039.15163,2790.49%
2022/06/3013739.1000.0039.101373,6263.78% 大買/鉅額交易
2022/03/1800.001340.0040.00-132,089-0.62%
2022/02/2300.001041.5041.50-102,530-0.40%
2022/01/122043.7500.0043.75202,1070.95%
2021/10/223143.9600.0043.90313,7620.82%
2021/10/1300.005042.5542.35-504,335-1.15%
2021/10/1200.0030045.6345.35-3004,277-7.01% 大賣/鉅額交易
2021/10/0800.0032647.0946.85-3264,269-7.64% 大賣/鉅額交易
2021/09/1700.004652.5052.50-464,683-0.98%
2021/08/1300.00348.5848.40-36,581-0.05%
2021/06/3051053.3600.0053.6051014,7753.45% 大買/鉅額交易
2021/06/1600.0031153.4253.10-31117,283-1.80% 大賣/鉅額交易
2021/05/28554.707955.2754.70-7416,578-0.45%
2021/02/269158.2000.0058.209112,3550.74%
2020/12/315156.1000.0056.105110,4020.49%
2020/11/1100.008360.9361.00-8316,728-0.50%
2020/09/3000.001368.6068.60-1329,577-0.04%
2020/09/1882172.6500.0072.7082135,4522.32% 大買/鉅額交易
2020/08/2500.004671.1270.70-4646,118-0.10%
2020/08/132865.4300.0064.002847,3290.06%
2020/07/2000.0092261.2466.00-92252,116-1.77% 大賣/鉅額交易
2020/03/1300.00728.3528.35-716,566-0.04%
2020/03/1000.00830.4030.40-814,978-0.05%
2020/01/071424.6000.0024.60142,8960.48%
2019/11/181324.7500.0024.75132,1210.61%
2019/11/111224.6500.0024.65122,0470.59%
2018/06/1900.003019.0018.95-30697-4.30%
2018/06/0800.003019.4119.30-30706-4.24%
2018/06/0400.003019.2619.30-30731-4.10%
2018/05/2900.003019.1519.25-30780-3.85%
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章